ZETA covers both upstream and midstream as well as downstream processing in this major project. A plant for the production of mAb-like bulk active ingredients is implemented, which includes the cultivation of mammalian cells in a fed-batch system, the cell harvest and subsequent purification steps. The plant is designed in such a way that there is a high degree of change-over efficiency when changing the production of different products.
